Angle plc announces board reshuffle with two departures

LONDON - ANGLE plc (AIM:AGL OTCQX:ANPCY), a prominent player in the liquid biopsy industry, has announced changes to its board with the upcoming retirement of Non-Executive Director Brian Howlett and the immediate resignation of Non-Executive Director Juliet Thompson. The company, known for its Parsortix® PC1 System which captures circulating tumor cells (CTCs) from blood samples, is currently reviewing its board’s structure and composition in light of these departures.

Howlett’s retirement will become effective at the company’s forthcoming Annual General Meeting (AGM), marking the end of his 12-year tenure with ANGLE. Thompson’s resignation takes effect immediately, after two and a half years with the company. Jan Groen, ANGLE’s Chairman, expressed gratitude for both directors’ contributions and extended best wishes for their future endeavors.

The news comes as ANGLE continues to focus on its clinical services and diagnostic products, leveraging its Parsortix system and associated consumables and assays. The company operates GCLP-compliant laboratories providing assay development and clinical trial testing for pharmaceutical clients.

ANGLE’s Parsortix® PC1 System has been cleared by the FDA and boasts over 100 peer-reviewed publications attesting to its efficacy. The system enriches CTCs for subsequent analysis, although it does not itself identify, enumerate, or characterize CTCs. The company emphasizes that users are responsible for validating any downstream assays, and the device is not intended for use in disease management or treatment decisions as a standalone tool.

This board reshuffle reflects a period of transition for ANGLE as it continues to advance in the liquid biopsy sector. The company’s statement, based on a press release, indicates that further details regarding the board’s reconstitution will be disclosed in due course.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.